Hidenori Shiraha
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Hidenori Shiraha has a total of 172 co-authors. Here are the top co-authors by number of shared publications:
Akinobu Takaki
Department of Gastroenterology and Hepatology, Okayama University, Okayama, Japan
18 shared publications- Kazuhide Yamamoto
Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
15 shared publications - Kazuhiro Nouso
Department of Gastroenterology, Okayama City Hospital, Okayama, Japan
13 shared publications Shinichiro Nakamura
Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
13 shared publicationsHiroyuki Okada
12 shared publications- Fusao Ikeda
Department of Gastroenterology and Hepatology, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, Okayama, Japan
10 shared publications
Latest Publications
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1524 - The Efficacy of REIC/DKK-3 Gene Therapy for Cholangiocarcinoma
- 1 May 2018
- Published by Elsevier in Gastroenterology
- Vol. 154 (6)
Tu1524 - The Efficacy of REIC/DKK-3 Gene Therapy for Cholangiocarcinoma
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e15674
Prospective evaluation of the factors predicting the prognosis of advanced hepatocellular carcinoma (HCC) patients treated with sorafenib.
E15674 Background: Several factors including pro-angiogenic cytokines have been reported as predictive markers for the treatment effect of sorafenib in patients with HCC; however, many of them were determined based on the results of retrospective studies. Methods: In this prospective cohort study (UMIN000009771), we recruited advanced HCC patients who were treated with sorafenib, and periodically measured serum levels of eight pro-angiogenic cytokines, which were risk factors for the prognosis reported by us and others. The effect of the cytokine expressions before and at 2 (4) weeks after starting sorafenib and at PD, on progression free survival (PFS), overall survival (OS), and post progression survival (PPS) were evaluated. The effect of early appearance of adverse events within 30 days, which were reported as other risk factors, was also evaluated. Results: Eighty patients were enrolled. Median PFS and OS were 3.1 and 11.7 months, respectively. There was no statistically significant variable that could predict PFS, which included patients’ characteristics, cytokines before the therapy, and early onset of adverse events. However, PFS of the patients who showed the decrease of platelet-derived growth factor after 2 weeks (HR2.78, 95%CI 1.35-6.21, P=0.005) or vascular endothelial growth factor after 4 weeks (HR3.31, 95%CI 1.59-6.83, P=0.001) compared to the values before sorafenib treatment was short. OS was short in patients with poor performance status, large tumor size (>30mm), large tumor number (>5), high des-gamma-carboxyprothrombin (DCP, >100mAU/mL), high hepatocyte growth factor, and high angiopoietin-2 (Ang-2) before therapy, in addition to no hand foot syndrome within 30 days. Multivariate analysis with these factors revealed that high Ang-2 (HR2.25, 95%CI 1.08-4.86, p=0.029) and high DCP (HR3.55, 95%CI 1.25-12.7, p=0.014) were the independent risk factors for OS. High Ang-2 at PD could also be a marker of short PPS. Conclusions: The prediction of PFS, OS and PPS is possible by measuring serum pro-angiogenic cytokines at appropriate timing. Ang-2 is a key cytokine for predicting the prognosis of HCC patients treated with sorafenib.
- 20 May 2017
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 35 (15_suppl) , e15674
Prospective evaluation of the factors predicting the prognosis of advanced hepatocellular carcinoma (HCC) patients treated with sorafenib.
E15674 Background: Several factors including pro-angiogenic cytokines have been reported as predictive markers for the treatment effect of sorafenib in patients with HCC; however, many of them were determined based on the results of retrospective studies. Methods: In this prospective cohort study (UMIN000009771), we recruited advanced HCC patients who were treated with sorafenib, and periodically measured serum levels of eight pro-angiogenic cytokines, which were risk factors for the prognosis reported by us and others. The effect of the cytokine expressions before and at 2 (4) weeks after starting sorafenib and at PD, on progression free survival (PFS), overall survival (OS), and post progression survival (PPS) were evaluated. The effect of early appearance of adverse events within 30 days, which were reported as other risk factors, was also evaluated. Results: Eighty patients were enrolled. Median PFS and OS were 3.1 and 11.7 months, respectively. There was no statistically significant variable that could predict PFS, which included patients’ characteristics, cytokines before the therapy, and early onset of adverse events. However, PFS of the patients who showed the decrease of platelet-derived growth factor after 2 weeks (HR2.78, 95%CI 1.35-6.21, P=0.005) or vascular endothelial growth factor after 4 weeks (HR3.31, 95%CI 1.59-6.83, P=0.001) compared to the values before sorafenib treatment was short. OS was short in patients with poor performance status, large tumor size (>30mm), large tumor number (>5), high des-gamma-carboxyprothrombin (DCP, >100mAU/mL), high hepatocyte growth factor, and high angiopoietin-2 (Ang-2) before therapy, in addition to no hand foot syndrome within 30 days. Multivariate analysis with these factors revealed that high Ang-2 (HR2.25, 95%CI 1.08-4.86, p=0.029) and high DCP (HR3.55, 95%CI 1.25-12.7, p=0.014) were the independent risk factors for OS. High Ang-2 at PD could also be a marker of short PPS. Conclusions: The prediction of PFS, OS and PPS is possible by measuring serum pro-angiogenic cytokines at appropriate timing. Ang-2 is a key cytokine for predicting the prognosis of HCC patients treated with sorafenib.
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1122
Subclinical Pulmonary Hypertension is a Strong Risk of Post Living Donor Liver Transplantation Survival for Liver Cirrhosis
- 1 April 2017
- Published by Elsevier in Gastroenterology
- Vol. 152 (5) , S1122
Subclinical Pulmonary Hypertension is a Strong Risk of Post Living Donor Liver Transplantation Survival for Liver Cirrhosis
- 1 January 2017
- Published by Japan Society of Hepatology in Kanzo
- Vol. 58 (11) , 599-604
A sofosbuvir-based direct-acting antiviral treatment regimen exhibits a strong protective effect against post-liver transplantation chronic hepatitis C recurrence
肝移植後C型肝炎に対するDirect Acting Antivirals(DAA)治療効果を検討した.Genotype1は29症例で,ダクラタスビル+アスナプレビル(DCV+ASV)5例,ソホスブビル+レジパスビル(SOF+LDV)25例(含DCV+ASV無効1例),Genotype2が2症例でSOF+リバビリン治療を行った.DCV+ASVは5例中4例で治療完遂,3例でSustained viral response(SVR)24を達成.SOF+LDVは全例SVR24を達成.移植後2カ月以内の肝炎再燃例も含まれているが問題なく治療完遂可能であった.Genotype2はSVR24を達成.SOF中心レジメンで100%のSVR24達成率であり,移植後早期においても問題なくウイルス駆除達成可能であった.C型肝硬変の肝移植適応評価においてC型肝炎のネガティブインパクトはなくなったと言っても過言ではない.
- 1 January 2017
- Published by Japan Society of Hepatology in Kanzo
- Vol. 58 (11) , 599-604
A sofosbuvir-based direct-acting antiviral treatment regimen exhibits a strong protective effect against post-liver transplantation chronic hepatitis C recurrence
肝移植後C型肝炎に対するDirect Acting Antivirals(DAA)治療効果を検討した.Genotype1は29症例で,ダクラタスビル+アスナプレビル(DCV+ASV)5例,ソホスブビル+レジパスビル(SOF+LDV)25例(含DCV+ASV無効1例),Genotype2が2症例でSOF+リバビリン治療を行った.DCV+ASVは5例中4例で治療完遂,3例でSustained viral response(SVR)24を達成.SOF+LDVは全例SVR24を達成.移植後2カ月以内の肝炎再燃例も含まれているが問題なく治療完遂可能であった.Genotype2はSVR24を達成.SOF中心レジメンで100%のSVR24達成率であり,移植後早期においても問題なくウイルス駆除達成可能であった.C型肝硬変の肝移植適応評価においてC型肝炎のネガティブインパクトはなくなったと言っても過言ではない.
- 1 January 2017
- Published by Japan Society of Hepatology in Kanzo
- Vol. 58 (8) , 427-434
Sufficient management of alert system of positive test results for HBV and HCV infection in electronic medical chart for facilitating hepatological consultation
非肝臓専門診療科で実施される肝炎ウイルス検査の結果が受検者に適切に説明されるように,当院では2013年に電子カルテ上で検査陽性を知らせるアラートの自動表示システムを導入した.このシステムを利用して担当医が説明した割合は28%と不十分であったため,検査実施診療科了解のもと検査陽性者へ検査報告書を郵送し,検査陽性者への報告率は89%と改善した.肝臓専門医への紹介状と返信用書類を同封,郵送半年後に肝臓専門医受診を確認できていない場合は再送し,肝炎専門医受診把握率は49%から72%に改善した(p<0.001).検査報告書再送で肝精査の必要性に気づき肝臓専門医を受診し,肝炎治療を受けた症例もあった.肝炎ウイルス検査陽性者への報告を徹底することは肝臓専門医受診率の向上や適切な肝炎治療の受療に有用である.
- 1 January 2017
- Published by Japan Society of Hepatology in Kanzo
- Vol. 58 (8) , 427-434
Sufficient management of alert system of positive test results for HBV and HCV infection in electronic medical chart for facilitating hepatological consultation
非肝臓専門診療科で実施される肝炎ウイルス検査の結果が受検者に適切に説明されるように,当院では2013年に電子カルテ上で検査陽性を知らせるアラートの自動表示システムを導入した.このシステムを利用して担当医が説明した割合は28%と不十分であったため,検査実施診療科了解のもと検査陽性者へ検査報告書を郵送し,検査陽性者への報告率は89%と改善した.肝臓専門医への紹介状と返信用書類を同封,郵送半年後に肝臓専門医受診を確認できていない場合は再送し,肝炎専門医受診把握率は49%から72%に改善した(p<0.001).検査報告書再送で肝精査の必要性に気づき肝臓専門医を受診し,肝炎治療を受けた症例もあった.肝炎ウイルス検査陽性者への報告を徹底することは肝臓専門医受診率の向上や適切な肝炎治療の受療に有用である.
- 1 August 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (4) , S170
Development of a novel REIC/Dkk-3-encoding adenoviral agent for the treatment of pancreatic cancer
- 1 August 2016
- Published by Elsevier in Pancreatology
- Vol. 16 (4) , S170
Development of a novel REIC/Dkk-3-encoding adenoviral agent for the treatment of pancreatic cancer
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1135
Mo1508 The Pattern of Recurrence Associated With the Prognosis of the Patients With Hepatocellular Carcinoma After Radiofrequency Ablation
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1135
Mo1508 The Pattern of Recurrence Associated With the Prognosis of the Patients With Hepatocellular Carcinoma After Radiofrequency Ablation
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S614
Su2023 Changes of Immunoglobulin-Bound Glycans in Patients With Gastro-Intestinal Cancers
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S614
Su2023 Changes of Immunoglobulin-Bound Glycans in Patients With Gastro-Intestinal Cancers
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1153
Tu1627 Promising Therapeutic Efficacy of a Novel REIC/Dkk-3 Expressing Adenoviral Vector for Hepatocellular Carcinoma
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S1153
Tu1627 Promising Therapeutic Efficacy of a Novel REIC/Dkk-3 Expressing Adenoviral Vector for Hepatocellular Carcinoma
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S294
Sa1354 Development of a Novel REIC/DKK-3-Encoding Adenoviral Agent: Its Robust and Promising Therapeutic Effects in Pancreatic Cancer
- 1 April 2016
- Published by Elsevier in Gastroenterology
- Vol. 150 (4) , S294
Sa1354 Development of a Novel REIC/DKK-3-Encoding Adenoviral Agent: Its Robust and Promising Therapeutic Effects in Pancreatic Cancer